keynote 10: pembrolizumab vs docetaxel for nsclc
Published 6 years ago • 155 plays • Length 3:52Download video MP4
Download video MP3
Similar videos
-
1:57
keynote-010: pembrolizumab versus docetaxel in advanced pd-l1-positive nsclc
-
1:22
updated outcomes of keynote-010 of pembrolizumab for nsclc
-
0:31
david gandara, md, discusses pembrolizumab vs docetaxel for previously treated nsclc patients
-
3:13
latest data from keynote 42: pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit...
-
2:56
keynote-010: pembrolizumab, anti-pd-1, for advanced nsclc with pd-l1 expression
-
1:37
keynote-010 shows overall survival benefit of pembrolizumab in nsclc
-
8:04
long-term management on immunotherapy for adv. nsclc: insights from keynote-010 (bmic-066)
-
3:04
keynote-024 update: pembrolizumab vs platinum-based chemotherapy in nsclc
-
2:30
association between ttmb and clinical outcomes with pembrolizumab alone in pd-l1-positive advanc...
-
3:44
pembrolizumab plus platinum-based chemotherapy for metastatic nsclc
-
6:32
latest results from keynote-181: pembrolizumab versus chemotherapy as a second-line therapy for ...
-
6:06
atezolizumab monotherapy vs docetaxel in 2nd and 3rd line nsclc
-
1:47
quality of life results from pembrolizumab vs chemotherapy in gastric or gastroesophageal juncti...
-
3:44
pembrolizumab plus chemo shows prolonged os and pfs improvement vs chemo for squamous nsclc
-
0:51
pembrolizumab increases long-term survival in patients with advanced nsclc
-
7:13
first-line pembrolizumab plus chemotherapy for patients with advanced squamous nsclc: 3-year fol...
-
1:57
keynote 091: adjuvant pembrolizumab - onctalk lung 2023
-
3:07
the keynote-001 trial: a breakthrough for pembrolizumab
-
1:39
pembrolizumab and epacadostat for nsclc: echo-306/keynote-715